1) Date of CV update: Febuary, 3rd, 2012 2) Personal data:
a) Name: Scott A. Small b) Birthdate: August, 7, 1961 c) Birthplace: Monticello, New York, USA d) Citizenship: USA
May, 1986; B.A. in experimental psychology (summa cum laude); New York University May, 1992; M.D.; Columbia University
• July, 1992- June, 1993; Internship in Internal Medicine; UCLA Medical Center
• July, 1993- June, 1996; Residency in Neurology: Columbia University Medical
• July, 1995- June, 1996; Chief Residency in Neurology: Columbia University Medical
• July, 1996- June, 1998; Post-doctoral Clinical Fellowship in Alzheimer’s disease and
Aging: Columbia University Medical Center.
a) NYS License to practice medicine: 1992 (license # 193749) b) American Board of Psychiatry and Neurology: 1997, certification in Neurology only.
6) Military service: 1979-1982; Israel Defense Forces; Special Operations Unit (Sayeret Golani) 7) Professional organizations and societies:
• Society for Neuroscience • Memory Disorders Research Society
• July, 1996- June, 1998; Clinical Fellow in Neurology; Columbia University
• July, 1998- June, 2006: Assistant Professor of Neurology Columbia University.
• July, 1999- June, 2001: Herbert Irving Assistant Professor of Neurology
• July, 2002-present: Member, Interdepartmental Doctoral Program in Neurobiology
• July, 2006-June, 2010: Associate Professor of Neurology (with tenure)
• July, 2010-present: Professor of Neurology (with tenure).
• July, 1996-June, 1998; Clinical Fellow in Neurology; Columbia University Medical
• July, 1998-June, 2006: Assistant Attending Neurologist; Columbia University
• July, 2006-June, 2010: Associate Attending Neurologist; Columbia University
• July, 2010-present: Attending Neurologist; Columbia University Medical Center
• 1986; University Award for Distinguished Honors Thesis, NYU
• 1986; Founders Day Award in recognition of achieving highest bracket of • scholastic preferment, NYU
• 1999; Irving Center Scholar Award, Columbia University
• 2000; AFAR Paul Beeson Physician Faculty Scholar in Aging Research Award
• 2002;JanSwammerdam Lecture in Neuroscience, University of Amsterdam
• 2002; McKnight Neuroscience of Brain Disorders Award
• 2002: Elected to the Memory Disorders Research Society • 2004: McDonnell Foundation Award
• 2006: Elected to American Neurological Association
• 2006: The Derek Denny-Brown Young Neurological Scholar Award,
• 2006: The Harold and Golden Lamport Award for Excellence in Clinical Science
11) Fellowship and grant support: A. Principal Investigator
• 2000-2003; AFAR Paul Beeson Physician Faculty Scholar in Aging Research Award,
“Functional analysis of the hippocampal formation in age-related memory decline.” $142,000 per year.
• 2000-2005; K23-AG00946 , NIH/NIA; “Longitudinal Analysis of Age Related
• 2000-2005; P50 AG08702 (Shelanski), NIH/NIA; PI Project 3: “fMRI Analysis of
Hippocampal Regions in Aging and Alzheimer's Disease”. $119.026 per year.
• 2003-2006; MEFN CU51800201, McKnight Neuroscience of Brain Disorders Award;
“Alzheimer’s Disease Diagnosis and Drug Development Using Microscopic-Metabolic MRI.” $90,909 per year.
• 2004-2007; The James S. McDonnell Foundation; “A functional-to-molecular
approach for investigating brain dysfunction”. $152,866 per year.
• 2004-2005; The High Q Foundation; “High Resolution Functioning Imaging Applied
to Huntington’s Disease.” $139,591 per year.
• 2002-2009; DAAD19-02-01-0267, DARPA, “Imaging Correlates of Neurogenesis in
• 2006-2009; Alzheimer’s Association; “Retromer-Mutant Mice as a Model of Late-
Onset Alzheimer’s Disease.” $81,086 per year
• 2008-2010; Anonymous Foundation; “Protein Sorting Defects and the Cell Biology
of Alzheimer’s Disease.” $146,997 per year.
• 2007-2010; Broitman Foundation; “The Broitman Program for Cognitive Disorders.”
• 2005-2010; P50 AG08702 (Shelanski), NIH/NIA; PI Project 1: “Imaging
Hippocampal Regions in MCI”. $125,000 per year.
• 2005-2010; R01, AG025161 NIH/NIA; “MRI and Mouse Models of Alzheimer’s
• 2009-2014; 5R01AG034618-02, NIH/NIA; “Histone Acetylation and Cognitive
• 2009-2014; Mars; “Understanding the Role of CF With Regard to Brain function and Cognition”. $503,950 per year. • 2010-2013; NYSTEM, Scott Small/Richard Sloan (Co-PI). Exercise and
• 2010-2015; R01, 2R01AG025161-05A1, NIH/NIA; “fMRI and Mouse Models of
Alzheimer’s Disease”. $205,000 per year
• 2010-2015; 1R01AG035015-01A1; NIH/NIA; “Exercise, Age-Related Memory
Decline, and Hippocampal Function”. $437,016 per year.
• 2011-2016; 1R01MH093398-01A1; NIH/NIA; “Longitudinal Imaging of Patients at
Clinical Risk for Psychosis”. $365,250 per year.
B. Co-investigator/ Co-mentor/ Consultant
• 2002-2007; K01AG21548-01 NIH/NIA, Matthias H. Tabert PI; “Olfaction and early
diagnosis of AD”. Dr. Small role as co-mentor is to contribute to the training o Dr. Tabert and to aid in developing an odor-induced fMRI approach as a potential diagnostic tool for Alzheimer’s disease.
• 2003-2008; R01 AG22381 VETSA, NIH/NIA, William S. Kremen PI; “Longitudinal
MRI twin study of aging”. Dr. Small’s role as a consultant is to implement an imaging approach developed in his laboratory in comparing the brains of twins as they age.
• 2004-2009; P01 AG07232, NIH/NIA, Richard Mayeux PI; “The Epidemiology of
dementia in an urban community: A continuation of a cross-cultural investigation of dementia in an upper Manhattan community”. Dr. Small’s role as co-principle investigator of the ‘MRI imaging core’ is to apply the imaging technique developed by Dr. Small’s lab to detect metabolic brain patterns in 1000 healthy elders.
• 2004-2009; NIH/NIA, Tae-Wan Kim PI; “Natural product therapeutics in
Alzheimer’s disease”. Dr. Small’s role as co-investigator is to apply imaging techniques developed in his lab to transgenic mouse models of Alzheimer’ disease, testing whether the compounds under investigation can correct metabolic defects.
• 2004-2009; NIHM, Marc Laruelle PI; "Dopamine neurobiology in schizophrenia”.
Dr. Small’s role as co-investigator is to apply imaging techniques developed in his lab to transgenic mouse models of schizophrenia, mapping patterns of dysfunction
• 2004-2007; Anonymous foundation, Ron Liem PI; “Transgenic models for
Alzheimer’s disease”. Dr. Small has two roles; one is to develop a mouse model of sporadic Alzheimer’s disease, based on microarray findings from his lab; and the other is to image mouse models of familiar and sporadic Alzheimer’s disease.
• 2005-20010; P50 AG08702 (Shelanski) NIH/NIA; Tae-Wan Kim PI Project 3:
“Protein trafficking in sporadic Alzheimer’s disease”. Dr. Small’s role as co-principal investigator is to further explore a trafficking pathway isolated by microarray analysis, implicated in Alzheimer’s disease.
• 2006-2012; 5K08AG027476-05, NIH/NIA, Herman Moreno PI. Mouse fMRI and
calcium dynamics in Alzheimer’s pathophysiology.
• 2007-2011; McDonnell Foundation; “Adult Neurogenesis: Bridging the Gap Between
• 2008-2012; NIH, Elisa Konofagou PI; ‘Optimization of Ultrasound-Induced Blood-
Brain Barrier Opening (09/30/08-08/31/13).
• 2008-2010; Kinetics Foundation, Elisa Konofagou PI. Ultrasound-induced molecular
• 2009-2014; NIH/NIMH, Stephan Rayport PI. Therapeutic potential of GLS1 inhibition
• 2011-2015; 1K23MH090563-01A1, NIH/NIMH, Scott Schobel PI. Cross-species
12) Departmental and University Committees:
• 1997-present; Residency selection committee, Neurology Department.
• 2002-present; Graduate student selection committee, Center for Neurobiology and
• 2002-present; MD-PhD selection committee.
13) Teaching experience and responsibilities:
• 1997-present; annual attending duties on the Neurology ward service.
• 2001-present; the practical component of the Clinical Practice I Clerkship Program,
where first year medical students join me in my clinical practice.
• 2002-2004; Weekly Neurobehavior rounds, Harlem Hospital.
• 2002-present; Annual CME course at Columbia University on Alzheimer’s disease
• Started in 2005; Annual lecture on functional imaging in a graduate course offered in
the Center for Neurobiology and Behavior (Biology of neurologic & psychiatric disorders, G4100.001)
• Starting in 2006; Annual lectures on Alzheimer’s disease, as part of a new
undergraduate course offered by the Kavli Institute of Brain Science at Columbia University (W3005y Neurobiology II: Neuronal circuits).
• 1999-2002; Co-mentored Ralf Meckle a graduate student in the department of
Biomedical Engineering. Degree conferred 2002.
• 2002-2007; Co-mentoring Matthias Tabert in his K-award on odor-induce fMRI as a
potential diagnostic tool in Alzheimer’s disease.
• 2002-2003; Mentored Aimee Pierce, a Doris Duke clinical research fellow in my lab,
on fMRI/microarray approaches to Alzheimer’s disease
• 2003-2004; Co-mentored Yvette Bordelon, a clinical post-doctoral fellow in my lab,
on using fMRI to map dysfunction in Huntington’s disease.
• 2004-2005; Mentored Dan Huddleston, a Doris Duke clinical research fellow in my
• 2003-2005; Mentored Herman Moreno, a clinical post-doctoral fellow in my lab, on
using mouse MRI to map dysfunction and for drug development.
• 2004-2008; Mentoring Nicole Lewandowski, a graduate student in my lab, on using
MRI to map dysfunction in patients with schizophrenia and in mouse models of schizophrenia.
• 2004-2007; Co-mentored Peter Ferrazzano, a clinical fellow in pediatric critical care,
who is working in my lab learning how to use mouse MRI to map metabolic dysfunction associated with Diabetes.
• 2006-Present; Mentoring Sidonie Jones, a graduate student in my lab, on using MRI to
• 2009: First year neurology residents rotate in Aging and Dementia clinic
a) Editorial: reviewer for the following journals-- Annals of Neurology, Journal of
Neuroscience, Lancet, Nature Neuroscience, Neurology, New England Journal of Medicine, Neuron, PLoS Medicine, Proceedings of the National Academy of Science,
b) Consultative • 2002; National Scientific Advisory Council for the 2002 American Federation of
• 2003-present; NIH-NIA ad hoc reviewer • 2003-present; Institute for the Study on Aging, Scientific Advisory Board
• 2004: NIH-NIA, chairman of Technical review Group for RFP 260-04-15
A. Original Peer-Reviewed Articles: • Small SA. The Effect of Mood on Word Recognition. Bulletin of the Psychonomic
• Small SA and Robbins CJ. The Influence of Induced Depressed Mood on Visual
Recognition Threshold: Predictive Ambiguity of Associative Network Models of Mood and Cognition. Cognitive Therapy and Research. 1988; 12: 295-304.
• Mackey SL, Glanzman DL, Small SA, Dyke AM, Kandel ER, and Hawkins RD. Tail
shock produces inhibition as well as sensitization of the siphon-withdrawal reflex of Aplysia: Possible role presynaptic inhibition mediated by the peptide Phe-Met-Arg-Phe-Nh2. Proceedings of the National Academy of Sciences. 1987; 84: 8730-8734.
• Small SA, Kandel ER, and Hawkins RD. Activity Dependent Enhancement of
Presynaptic Inhibition in Aplysia Sensory Neurons. Science. 1989; 243: 1603-1606
• Small SA, Lavic N, Kandel ER, and Hawkins RD. Identified FMRF-amide
Immunoreactive Neuron LPL16 in the left Pleural Ganglion of Aplysia Produces Presynaptic Inhibition of Siphon-sensory Neurons. Journal of Neuroscience. 1992; 12: 1616-1627.
• Zhuo M., Small SA, Kandel ER, and Hawkins RD. Nitric Oxide and Carbon
Monoxide Produce Activity Dependent Long Term Synaptic Enhancement in Hippocampus. Science. 1993; 269: 1946-1950.
• Manly JJ, Jacobs DM, Sano M, Bell K., Merchant CA, Small SA, and Stern Y.
Cognitive test performance among nondemented elderly African Americans and Whites. Neurology. 1998; 50:1238-1245.
• Small SA, Perera GM, DeLaPaz R, Mayeux R, and Stern Y. Differential regional
dysfunction of the hippocampal formation among elderly with memory decline and Alzheimer’s disease. Annals of Neurology. 1999; 45: 466-472.
• Small SA, Stern Y, Tang M, and Mayeux R. Selective decline in memory function
among healthy elderly. Neurology. 1999; 52:1392-1396.
• Manly JJ, Jacobs DM, Sano M, Bell B, Merchant CA, Small SA, Stern Y. Effect of
literacy on neuropsychological test performance in nondemented, education-matched elders. Journal of the International Neuropsychology Society. 1999; 5: 203-212.
• Mayeux R, Tang MX, Jacobs DM, Manley J, Bell K, Merchant C, Small SA, Stern Y.
Wisniewksi HM, Mehta PD. Plasma amyloid beta-peptide 1-42 and incipient Alzheimer’s disease. Annals of Neurology. 1999; 46(3): 412-416.
• Moroney J, Tang MX, Stern Y, Lerglund L, Small SA, Merchant C, Bell K, Mayeux R.
Low-density lipoprotein cholesterol and the risk of dementia after stroke. JAMA. 1999; 282: 254-260
• Small SA, Nava AS, Perera GM, Delapaz R, Stern Y. Evaluating the function of
hippocampal subregions with high-resolution MRI in Alzheimer's disease and aging. Microscopy Researchand Techniques. 2000;51(1):101-108.
• Small SA, Wu EX, Bartsch D, Perera GM, Lacefield CO, DeLaPaz R, Mayeux R, Stern
Y, and Kandel ER. Imaging Physiologic Dysfunction of Individual Hippocampal Subregions in Humans and Genetically Modified Mice. Neuron. 2000; 28: 653-664.
• Manly JJ. Merchant CA. Jacobs DM. Small SA. Bell K. Ferin M. Mayeux R.
Endogenous estrogen levels and Alzheimer's disease among postmenopausal women. Neurology. 54(4):833-7, 2000
• Small SA, Nava AS, Tsai WY, DeLaPaz R, Mayeux R, Stern Y. Circuit mechanisms
underlying memory encoding and retrieval in the long axis of the hippocampal formation. Nature Neuroscience. 2001; 4: 442-449.
• Mayeux R. Small SA. Tang M. Tycko B. Stern Y. Memory performance in healthy
elderly without Alzheimer's disease: effects of time and apolipoprotein-E. Neurobiology of Aging. 22(4):683-689, 2001
• Manly JJ. Jacobs DM. Touradji P. Small SA. Stern Y. Reading level attenuates
differences in neuropsychological test performance between African American and White elders. Journal of the International Neuropsychological Society. 8(3):341-348, 2002
• Small SA, Tsai WY, DeLaPaz R, Mayeux R, Stern Y. Imaging hippocampal function
across the human life span: Is memory decline normal or not? Annals of Neurology. 2002; 51: 290-295.
• Hasker PD, Small SA, Stern Y, Mayeux R, Feldstein SN, Keller FR. Acquisition,
recall, and forgetting of verbal information in long-term memory by young, middle-aged, and elderly individuals. Cortex. 2003;39:1063-1091.
• Small SA. Measuring correlates of brain metabolism with high-resolution MRI: A
promising approach for diagnosing Alzheimer’s disease and mapping its course. Alzheimer’s disease and Related Disorders. 2003, 17: 154-161.
• Small SA, Chawla MK, Buonocore M, Rapp P, Barnes CA. Imaging correlates of
brain function in monkeys and rats isolates a hippocampal subregion differentially vulnerable to aging. Proceedings of the National Academy of Science. 2004; 18: 7181-7186.
• Small SA, Kent K, Pierce A, Leung C, Kang MS, Okada H, Honig L, Vonsattel JP,
Kim TW. Model-guided microarray implicates the retromer complex in Alzheimer’s disease. Annals of Neurology. 2005; 58: 909-919.
• *Moreno H, Brown T, Small SA. An MRI technique for mapping cerebral blood
volume longitudinally in mice. NMR in Biomedicine, 2006; 19:535-543.
• *Pereira, AC, Huddleston DE, Brickman AM, Sosunov AA, Hen R, McKhann GM,
Sloan R, Gage FH, Brown TR, Small SA. An in vivo correlate of exercise-induced neurogenesis in the adult dentate gyrus. Proceedings of the National Academy of Science, 2007; 104: 5638-3543.
• Choi, JJ, Pernot M, Small SA, Konofagou EE. Non-invasive, Transcranial, and
Localized Opening of the Blood-Brain Barrier in Mice using Focused Ultrasound – A Feasibility Study, Journal of Ultrasound in Medicine and Biology. 2007; 33: 95-104.
• *Kent K, Hess K, Tonegawa S, Small SA. CA3 NMDA receptors are required for the
experience-dependent shift in hippocampal long-axis activity. Hippocampus. 2007; 17: 1003-1011.
• Choi JJ, Pernot M, Brown TR, Small SA, Konofagou EE. Spatio-temporal analysis
of molecular delivery through the blood-brain barrier using focused ultrasound. Physics in Medicine and Biology. 2007; 52: 5509-5530.
• *Moreno H, Wu W, Lee T, Brickman A, Mayeux R, Brown T, Small SA. Imaging
the Aβ-related neurotoxity of Alzheimer’s disease. Archives of Neurology. 2007; 64: 1467-1477.
• Louis ED, Brickman AM, DeCarli C, Small SA, Marder K, Schupf N, Brown TR.
Archives of Neurology. 2008; 65:1649-1654.
• Brickman AM, Schupf N, Manly JJ, Luchsinger JA, Andrews H, Tang MX, Reitz C,
Small SA, Mayeux R, DeCarli C, Brown TR.Archives of Neurology. 2008;65:1053-1061.
• *Wu W, Brickman AM, Luchsinger J, Ferrazano P, Pichiule P, Mistuhiro Y, Brown T,
DeCarli C, Barnes C, Mayeux R, Vannuccci S, Small SA. The brain in the age of old: The hippocampal formation is targeted differentially by diseases of late-life. Annals of Neurology. 2008; 64: 689-706
• Choi, J.J., Wang, S., Brown, T.R., Small, S.A., Duff, K.E., and Konofagou, E.E.
Noninvasive and transient blood-brain barrier opening in the hippocampus of Alzheimer's double transgenic mice using focused ultrasound. Ultrasonic Imaging. 2008: 30, 189-200.
• Luchsinger JA, Brickman AM, Reitz C, Cho SJ, Schupf N, Manly JJ, Tang MX,
Small SA, Mayuex R, DeCarli C, Brown TR. Subclinical cerebrovascular disease in mild cognitive impairment. Neurology. 2009; 11: 450-456.
• Louis ED, Brickman AM, DeCarli C, Small SA, Marder K, Schupf N, Brown TR.
Archives of Neurology. 2008; 65: 1649-1654.
• Pickford F, Masliah E, Britschgi M, Lucin K, Narasimhan R, Jaeger PA, Small SA,
Spencer B, Rockenstein E, Levine B. Wyss-Coray T. The autophagy-related proteins beclin 1 shows reduced expression in early Alzheimer’s dsiease and regualtes amyloid beta accumulation in mice. Journal of Clinical Investigation. 2008; 118: 2190-2199.
• *Gaisler-Salomon I, Miller GM, Chuhma N, Lee S, Zhang H, Ghoddoussi F,
Lewandowski N, Fairhurst S, Want Y, Conjard-Duplany A, Masson J, Balsam P, Hen R, Arancio O, Galloway MP, Moore HM, Small SA, Rayport, S. Glutaminase-deficient mice display hippocampal hyperactivity, insensitivity to pro-psychotic durges and potentiated inhibition: Relevance to schizophrenia. Neuropsychopharmacology. 2009: 34:2305-2322.
• Luchsinger JA, Brickman AM, Reitz C, Cho SJ, Schupf N, Manly JJ, Tang MX,
Small SA, Mayeux R, DeCarli C, Brown TRNeurology. 2009, 73:450-455
• *Schobel S, Lewandowski N, Corcoran C, Moore H, Brown T, Malaspina D, and
Small, SA . The CA1 subfield of the hippocampal formation is differentially targeted by schizophrenia and related psychotic disorders. Archives of General Psychiatry. 2009; 66:938-946
• *Reitz C, Brickman AM, Brown TR, Manly J, DeCarli C, Small SA, Mayeux R.
Archives of Neurology. 2009;66:11385-1392.
• Borogovac A, Habeck C, Small SA, Asllani I. Mapping brain function using a 30-day
interval between baseline and activation: a novel arterial spin labeling fMRI approach. Journal of Cerebral Blood Flow and Metabolism. 2010 Jul 21th (ahead of print)
• *Lewandowski NM, Ju S, Verbitsky M, Ross B, Geddie ML, Rockenstein E, Adame
A, Muhammad A, Vonsattel JP, Ringe D, Cote L, Lindquist S, Masliah E, Petsko GA, Marder K, Clark LN, Small SAProceeding of the National Academy of Science. 2010;107:16970-16675
ippocampus. 2010, Sep 7th (ahead of print).
• Lane RF, Raines SM, Steele JW, Ehrlich ME, Lah JA, Small SA, Tanzi RE, Attie AD,
Gandy S. Diabetes-associated SorCS1 regulates Alzheimer’s amyloid-β metabolism: Evidence for involvement of SorL1 and the retromer complex. Journal of Neuroscience. 2010;30:13110-13115
• Viera SI, Rebelo S, Esselmann H, Wiltfang J, Lah J, Lane R, Small SA, Gandy S, da
Cruze e Silva E, da cruz e Sliva O. Retrieval fo the Alzheimer’s amyloid precursor protein from the endosomes to the TGN is S655 phosphorylation state-dependent and retromer-mediated. Molecular Neurodegeneration. 2010;5:40.
• Lane RF, Gatson JW, Small SA, Ehrlich ME, Gandy S
Molecular Neurodegeneration. 2010 Dec 30;5:62
• Dall'Armi C, Hurtado-Lorenzo A, Tian H, Morel E, Nezu A, Chan RB, Yu WH,
Robinson KS, Yeku O, Small SA, Duff K, Frohman MA, Wenk MR, Yamamoto A, Di Paolo GNature Communications. 2010;1:142.
• *Moreno H, Burghardt NS, Vela-Duarte D, Masciotti J, Hua F, Fenton AA, Schwaller
B, Small SAHippocampus. 2011, ahead of print
• Blum S, Luchsinger JA, Manly JJ, Schupf N, Stern Y, Brown TR, DeCarli C, Small
SA, Mayeux R, Brickman AMNeurology. 2012 , 3;78:38-46.
• Chan RB, Oliveira TG, Cortes EP, Honig LS, Duff KE, Small SA, Wenk MR, Shui G,
Di Paolo GJournal of Biological Chemistry. 2012, 287:2678-88
• Liu L, Drouet V, Wu JW, Witter MP, Small SA, Clelland C, Duff K. Trans-Synaptic
Spread of Tau Pathology In Vivo. Plos One. 2012, 7; e31302
B. Review Articles and Editorials • Small SA. Age-related memory decline; current concepts and future directions.
Archives of Neurology. 2001; 58:360-364.
• Small SA. The longitudinal axis of the hippocampal formation: Its anatomy, circuitry
and role in cognitive function. Reviews in the Neurosciences. 2002; 13: 183-194.
• Small SA. Imaging Alzheimer’s disease. Current Neurology & Neuroscience Reports.
• Pierce A and Small SA. Combining brain imaging with microarray: Isolating
molecules underlying physiologic disorders of the brain. 2004; Neurochemical Research, 2004; 29: 1145-1152.
• Small SA. Quantifying cerebral blood flow: regional regulation with global
implications. Journal of Clinical Investigation. 2004; 114, 1046-1048.
• Small SA. Alzheimer disease, in living color. Nature Neuroscience. 2005; 8: 404-405.
• Lewandowski N and Small SA. Brain microarray: Finding needles in molecular
haystacks. Journal of Neuroscience. 2005; 9: 10341-10346.
• Huddleston D and Small SA. Technology insight: imaging amyloid plaques in the
living brain with positron emission tomography and MRI. Nature Clinical Practice Neurology. 2005; 1; 96-105.
• Small SA and Gandy S. Sorting through the cell biology of Alzheimer’s disease:
Intracellular pathways to pathogenesis. Neuron. 2006; 52 (15-31).
• Wu, W and Small SA. Imaging the earliest stages of Alzheimer’s disease. Current
Alzheimer Research. 2006; 3: 529-539.
• Pereira AC, Wu W, Small SA. Imaging-guided microarray: isolating molecular
profiles that dissociate Alzheimer’s disease from normal aging. Annals of the New York Academy of Sciences. 2007: 1097: 225-238.
• Small SA. Retromer sorting: a pathogenic pathway in late-onset Alzheimer disease.
Archives of Neurology. 2008; 65: 323-328
• Small, S.A., and Duff, K. . Linking Abeta and tau in late-onset Alzheimer's disease: a
dual pathway hypothesis. Neuron. 2008: 60, 534-542.
• Gaisler-Salomon I, Schobel SA, Small SA, Rayport S
Schizophrenia Bulletin. 2009; 45: 1037-1044.
• Brickman AM, Small SA, Fleisher A.
• Small SA, Schobel SA, Buxton RB, Witter MP, Barnes CA
Nature Reviews Neuroscience. 2011;12:585-601
• Small SA and Mayeux R. Delirium and Dementia. In Merritt’s Textbook of
Neurology. Rowland LP Ed. 11th Edition. Williams & Wilkins.
• Small SA and Mayeux R. Acquired and Hereditary Dementias. In Merritt’s
Textbook of Neurology. Rowland LP Ed. 11th Edition. Williams & Wilkins.
• Stern Y and Small SA. Imaging the consequences of Alzheimer’s disease pathology.
In Alzheimer’s diease; Advances in etiology pathogenesis and therapeutics. Iqbal K, Sisodia SS, Winblad B Eds. John Wiley & Sons.
• Small SA. The Neurobiological Correlates of Imaging. In Functional Imaging of the
Nervous System. D’Esposito M Ed. In press. CRC Press
• Gazzaley A, Small SA. Imaging Alzheimer’s Disease. In Functional Imaging of the
Nervous System. D’Esposito M Ed. In press. CRC Press
• Small SA. Imaging Alzheimer’s disease with MRI. In In Vivo MR Techniques in
Drug Discovery and Development. Beckmann N Ed. In press. CRC Press
• Small SA. Imaging Cognitive Aging. In Handbook of Models for Human Aging.
Conn PM Ed. In Press, Academic Press/Elsevier
• Small SA. Imaging metabolic defects in Alzheimer’s Disease with MRI. In Clinical
applications of functional Brain MRI. Rombouts S, Barkhof F, Scheltens P Eds. In Press. Oxford University Press
• Small SA and Heeger D. Functional Imaging of Cognition. In Principles of Neural
Sciences. Kandel ER and Schwartz JH, Jessel TM Eds. 5th Edition. In Preparation. McGraw-Hill
• Gandy S, Silva O, Suzuki T, Ehrlich M, Small SA. Amyloid precursor protein sorting
and processing: Transmitters, hormones, and protein phosphorylation mechanisms. In, Intracellular Traffic and Neurodegenerative Disorders, Research and Perspectives in Alzheimer’s disease. St. George-Hyslop P Editor. Springer-Verlag Berlin Heidlberg, 2009
• “High-Resolution Metabolic Brain Imaging”. US 2006/0008416 A1, January, 12th,
• “VPS35-Based Assays and Methods for Treating Alzheimer’s Disease”. US
• “Expression of RbAp48 in memory and aging and method related thereto”. US
• “Mice MRI for Drug Screening”. US 2007/0264200 A1, November, 15th, 2007
• “An MRI correlate of dentate gyrus neurogenesis”. US 2009/02461 A1, October, 1st,
• “Systems and methods for opening of the blood-brain barrier of a subject using
ultrasound”. US 2009 0005711 A1, October, 1st, 2009.
• March, 11, 1999; “Ethical debate over potential Viagra for the mind”, CNN.
• February, 1, 2000; “Is memory loss inevitable? Maybe not”, The New York Times
• December, 6, 2004; “The quest for memory drugs”, Newsweek. • December, 12, 2005; “The gene hunters”, The New Yorker.
• August, 19, 2007; “Lobes of Steel”, The New York Times
• May, 8, 2008; “Memory: Forgetting is the new normal”, Time Magazine
• December, 31, 2008; “Blood sugar control liked to memory decline”, The New York
• May 9, 2009; “The Alzheimer’s project”, HBO
• March, 25, 2010; “The Aging Brain”, The Charlie Rose show • February, 1, 2012; “Path is found for the spread of Alzheimer’s”, Front page, The
DOKUMENTIERTE PATIENTENAUFKLÄRUNG Basisinformation über die Hautstraffung mittels Radiofrequenz Die erste Sitzung wurde für den ________ geplant. Liebe Patientin, lieber Patient Sie haben sich für die Straffung der Haut mittels eines Radiofrequenzgerätes (RF) entschieden. Vor der ersten Sitzung wird die Ärztin/der Arzt mit Ihnen über diese Behandlung und die Möglichkeite
Medicine s Matters A guide to mechanisms for the prescribing, July 2006 DH INFORMATION READER BOX INSERT NEW IRB DH INFORMATION READER BOX HR / Workforce Document Purpose ROCR Ref: Gateway Ref: Medicines Matters: a guide to mechanisms for the prescribing, supply and administration of medicinesNational Practitioner Programme, DH Core Prescribing Group Publicat